Earnings per Share (EPS) (Basic): A company's net earnings or losses attributable to common shareholders per basic share basis.
Relmada Therapeutics, Inc. (RLMD) had Earnings per Share (EPS) (Basic) of $-0.22 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-19.05M |
|
-- |
|
-- |
|
$19.46M |
|
$-19.46M |
|
$0.41M |
|
$-19.05M |
|
$-18.50M |
|
$-19.05M |
|
$-19.05M |
|
$-19.05M |
|
$-18.50M |
|
$-19.46M |
|
$-19.46M |
|
86.60M |
|
86.60M |
|
|
Earnings per Share (EPS) (Basic) |
$-0.22 |
$-0.22 |
|
| Balance Sheet Financials | |
$235.34M |
|
-- |
|
$0.02M |
|
$235.36M |
|
$12.89M |
|
-- |
|
$3.74M |
|
$16.63M |
|
$218.73M |
|
$218.73M |
|
$218.73M |
|
104.89M |
|
| Cash Flow Statement Financials | |
$-15.07M |
|
$-135.23M |
|
$156.57M |
|
$3.50M |
|
$9.78M |
|
$6.28M |
|
$0.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.26 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.71% |
|
-8.71% |
|
-8.09% |
|
-8.71% |
|
$2.09 |
|
$-0.17 |
|
$-0.17 |
|